Skip to content
Triangle logo TriangleGet started
← Study library

NCT00831844 · REGISTRY CONDITION SEARCH

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2015-03-30

This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Disease Response

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Histologically confirmed malignant solid tumor, including the following: * Osteosarcoma * Ewing sarcoma/peripheral primitive neuroectodermal tumor * Rhabdomyosarcoma * Neuroblastoma * Wilms tumor * Synovial sarcoma * Hepatoblastoma * Adrenocortical carcinoma * Retinoblastoma * No known curative therapy or therapy proven to prolong survival with an acceptable quality of life exists * Radiographically measurable disease\*, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by MRI or CT scan or ≥ 10 mm by spiral CT scan * The following are not considered measurable disease: * Ascites, pleural effusions, or other malignant fluid collections * Bone marrow infiltration by tumor * Lesions detected only by non-MIBG nuclear medicine studies (e.g., bone scan) * Previously irradiated lesions that have not demonstrated clear progression post-radiotherapy * No known Central Nervous System (CNS) metastases unless they were treated by surgery or radiotherapy AND are stable with no recurrent lesions for ≥ 3 months * Lansky or Karnofsky performance status (PS) 50-100% OR Eastern Cooperative Oncology Group (ECOG) PS 0-2 * Absolute neutrophil count (ANC) ≥ 1,000/mm³ (\> 250/mm³ for patients with neuroblastoma) * Platelet count ≥ 75,000/mm³ (\> 25,000/mm³ for patients with neuroblastoma) (transfusion independent) * Hemoglobin ≥ 8.0 g/dL (≥ 7.5 g/dL for patients with neuroblastoma) (RBC transfusion allowed) * Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine normal based on age/gender as follows: * ≤ 0.4 mg/dL (for patients 1 to 5 months of age) * ≤ 0.5 mg/dL (for patients 6 to 11 months of age) * ≤ 0.6 mg/dL (for patients 1 year of age) * ≤ 0.8 mg/dL (for patients 2 to 5 years of age) * ≤ 1 mg/dL (for patients 6 to 9 years of age) * ≤ 1.2 mg/dL (for patients 10 to 12 years of age) * ≤ 1.5 mg/dL (males) or 1.4 mg/dL (females) (for patients 13 to 15 years of age) * ≤ 1.7 mg/dL (males) or 1.4 mg/dL (females) (for patients ≥ 16 years of age) * Total bilirubin ≤ 1.5 times upper limit of normal for age * Alanine transaminase (ALT) ≤ 110 U/L * Serum albumin ≥ 2 g/dL * Blood glucose normal * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after completion of study treatment * Able to comply with safety monitoring requirements of study * No history of allergic reactions attributed to compounds of similar chemical or biologic composition to study drug * No uncontrolled infection * No known type I or II diabetes mellitus * Recovered from prior chemotherapy, immunotherapy, or radiotherapy * More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) * At least 7 days since prior hematopoietic growth factors (14 days for pegfilgrastim) * At least 6 weeks since prior monoclonal antibody therapy * At least 7 days since other prior antineoplastic biologic agents * No prior monoclonal antibody targeting the IGF-IR * No prior small molecule kinase inhibitors of IGF-IR * At least 2 weeks since prior local palliative (small port) radiotherapy * At least 3 months since prior total-body irradiation, craniospinal radiotherapy, or radiotherapy to ≥ 50% of the pelvis * At least 6 weeks since other prior substantial bone marrow radiotherapy * At least 2 months since prior stem cell transplantation * No evidence of graft-versus-host disease * Concurrent corticosteroids allowed provided dose is stable or decreasing over the past 7 days * Intermittent use of corticosteroids to manage infusional reactions allowed * No other concurrent anticancer therapy, including chemotherapy, radiotherapy, immunotherapy, or biologic therapy * No other concurrent investigational agents * No concurrent insulin or growth hormone therapy
healthy Volunteers
false
maximum Age
30 Years
minimum Age
7 Months
sex
ALL
std Ages
  1. CHILD
  2. ADULT
Treatment arms and interventions
arm Groups
  1. description
    Group 1 - Recurrent or Refractory Hepatoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Biological: cixutumumab
    2. Other: laboratory biomarker analysis
    label
    Group 1 - Recurrent or Refractory Hepatoblastoma
    type
    EXPERIMENTAL
  2. description
    Group 2 - Recurrent or Refractory Synovial Sarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Biological: cixutumumab
    2. Other: laboratory biomarker analysis
    label
    Group 2 - Recurrent or Refractory Synovial Sarcoma
    type
    EXPERIMENTAL
  3. description
    Group 3 - Recurrent or Refractory Rhabdomyosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Biological: cixutumumab
    2. Other: laboratory biomarker analysis
    label
    Group 3 - Recurrent or Refractory Rhabdomyosarcoma
    type
    EXPERIMENTAL
  4. description
    Group 4 - Recurrent or Refractory Adrenocortical Carcinoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Biological: cixutumumab
    2. Other: laboratory biomarker analysis
    label
    Grp 4-Recurrent or Refractory Adrenocortical Carcinoma
    type
    EXPERIMENTAL
  5. description
    Group 5 - Recurrent or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Biological: cixutumumab
    2. Other: laboratory biomarker analysis
    label
    Grp 5-Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
    type
    EXPERIMENTAL
  6. description
    Group 6 - Recurrent or Refractory Neuroblastoma -meta-iodobenzylguanidine (MIBG) Positive Without Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Biological: cixutumumab
    2. Other: laboratory biomarker analysis
    label
    Grp 6 - Neuroblastoma-MIBG Positive Without Measurable Disease
    type
    EXPERIMENTAL
  7. description
    Group 7 - Recurrent or Refractory Neuroblastoma -With Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Biological: cixutumumab
    2. Other: laboratory biomarker analysis
    label
    Grp 7-Neuroblastoma with measurable disease
    type
    EXPERIMENTAL
  8. description
    Group 8 - Recurrent Osteosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Biological: cixutumumab
    2. Other: laboratory biomarker analysis
    label
    Group 8 - Recurrent Osteosarcoma
    type
    EXPERIMENTAL
  9. description
    Group 9 - Recurrent or Refractory Wilms Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Biological: cixutumumab
    2. Other: laboratory biomarker analysis
    label
    Group 9 - Recurrent or Refractory Wilms Tumor
    type
    EXPERIMENTAL
  10. description
    Group 10 - Recurrent or Refractory Retinoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Biological: cixutumumab
    2. Other: laboratory biomarker analysis
    label
    Group 10 - Recurrent or Refractory Retinoblastoma
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Group 1 - Recurrent or Refractory Hepatoblastoma
    2. Group 10 - Recurrent or Refractory Retinoblastoma
    3. Group 2 - Recurrent or Refractory Synovial Sarcoma
    4. Group 3 - Recurrent or Refractory Rhabdomyosarcoma
    5. Group 8 - Recurrent Osteosarcoma
    6. Group 9 - Recurrent or Refractory Wilms Tumor
    7. Grp 4-Recurrent or Refractory Adrenocortical Carcinoma
    8. Grp 5-Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
    9. Grp 6 - Neuroblastoma-MIBG Positive Without Measurable Disease
    10. Grp 7-Neuroblastoma with measurable disease
    description
    Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.
    name
    cixutumumab
    other Names
    1. anti-IGF-1R recombinant monoclonal antibody IMC-A12
    2. IMC-A12
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Group 1 - Recurrent or Refractory Hepatoblastoma
    2. Group 10 - Recurrent or Refractory Retinoblastoma
    3. Group 2 - Recurrent or Refractory Synovial Sarcoma
    4. Group 3 - Recurrent or Refractory Rhabdomyosarcoma
    5. Group 8 - Recurrent Osteosarcoma
    6. Group 9 - Recurrent or Refractory Wilms Tumor
    7. Grp 4-Recurrent or Refractory Adrenocortical Carcinoma
    8. Grp 5-Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
    9. Grp 6 - Neuroblastoma-MIBG Positive Without Measurable Disease
    10. Grp 7-Neuroblastoma with measurable disease
    description
    Correlative studies
    name
    laboratory biomarker analysis
    type
    OTHER
Study design
allocation
NON_RANDOMIZED
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
116
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Response rates will be calculated as the percent of patients whose best response is a Complete Response (CR) or Partial Response (PR).
    measure
    Disease Response
    time Frame
    First six treatment cycles - 24 weeks
Full study description
brief Summary
This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
detailed Description
PRIMARY OBJECTIVES: I. To determine the response rate to IMC-A12 (cixutumumab) administered in various strata of recurrent/refractory malignant solid tumors in childhood and young adulthood. II. To further define and describe the toxicities of IMC-A12. III. To further characterize the pharmacokinetics of IMC-A12. SECONDARY OBJECTIVES: I. To examine the relationship between tumor expression of insulin-like growth factor (IGF)-I, IGF-II, and IGF-I receptor (IR) and response to IMC-A12. II. To determine the human anti-human antibody (HAHA) response after treatment with IMC-A12. III. To further evaluate the effect of IMC-A12 on circulating levels of proteins involved in linear growth and glucose homeostasis, including IGF-I, IGF-II, IGF-BP3, growth hormone, insulin, and C-peptide. OUTLINE: This is a multicenter study. Patients are stratified according to disease type. Patients receive cixutumumab intravenously (IV) over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection periodically for correlative laboratory studies. Samples are analyzed for IGF-I, IGF-II, IGF-BP3, growth hormone, insulin, and C-peptide levels and for immunogenicity.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-6146fc7f0f9c87488c04
      requested nct id
      NCT00831844
      primary nct id
      NCT00831844
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      9d7960d89169a453f1ac7b2a50046538e920fc46c1e81576f7eac42f88243453
      payload sha256
      13d60f206fafed4c6696e0e0e9d0788414bbcc7489010d9d8be502e0cc08981c
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-6146fc7f0f9c87488c04
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00831844
      occurrences
      1. context exact
        NCT00831844
        end
        11
        exact text
        NCT00831844
        start
        0
      offset unit
      unicode_code_points
      query cond
      Childhood Liver Cancer
      query disease state id
      ds-liver-cancer-pediatric
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-liver-cancer-000.json
      source file sha256
      9d7960d89169a453f1ac7b2a50046538e920fc46c1e81576f7eac42f88243453
      source json pointer
      /studies/6/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      0f7e1fdea15a850875550580b5c881551da75cf5b552e51fecf3b77bd79e1b4f
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-ce76af26b328ae998a7d
      requested nct id
      NCT00831844
      primary nct id
      NCT00831844
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      4582dcc6b457179c698a287a06374cc412cac318126811f31cbc1d23c321cfb3
      payload sha256
      655cb707d32c073dc0a37b963b387aa775761d1ac67f0d2e3e1cf3069fc8117e
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-ce76af26b328ae998a7d
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00831844
      occurrences
      1. context exact
        NCT00831844
        end
        11
        exact text
        NCT00831844
        start
        0
      offset unit
      unicode_code_points
      query cond
      Childhood Adrenocortical Carcinoma
      query disease state id
      ds-adrenocortical-carcinoma-pediatric
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-adrenocortical-carcinoma-000.json
      source file sha256
      4582dcc6b457179c698a287a06374cc412cac318126811f31cbc1d23c321cfb3
      source json pointer
      /studies/1/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      0f7e1fdea15a850875550580b5c881551da75cf5b552e51fecf3b77bd79e1b4f
    3. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-f646bb7c95af0c2f77e2
      requested nct id
      NCT00831844
      primary nct id
      NCT00831844
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      0f0b1d47d700cf556d6212d53b7849c30874e411dbc1a4cfc2cbeef7e5d70ca8
      payload sha256
      f89dd4f462d9e33ba4b713eccd54c159b326446c21c0ab3f34665f43c6914560
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-f646bb7c95af0c2f77e2
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00831844
      occurrences
      1. context exact
        NCT00831844
        end
        11
        exact text
        NCT00831844
        start
        0
      offset unit
      unicode_code_points
      query cond
      Childhood Kidney Tumors
      query disease state id
      ds-childhood-kidney-tumors
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-kidney-tumors-000.json
      source file sha256
      0f0b1d47d700cf556d6212d53b7849c30874e411dbc1a4cfc2cbeef7e5d70ca8
      source json pointer
      /studies/14/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      0f7e1fdea15a850875550580b5c881551da75cf5b552e51fecf3b77bd79e1b4f

    Preserved source evidence · Not medical advice